This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Metformin and AGIs show potential for improved outcomes in COVID-19 patients with type 2 diabetes

Metformin and AGIs show potential for improved outcomes in COVID-19 patients with type 2 diabetes
The forest plot to describe adjusted Hazard ratio for in-hospital all-cause mortality in the multivariate Cox regression model. The names of covariates included in the cox regression model were listed on the left of the figure and adjusted HR, 95% CI and p-value were shown in lines and points. (p < 0.1: *; p < 0.01: **; p < 0.001: ***.). Credit: Molecular Biomedicine (2024). DOI: 10.1186/s43556-024-00183-1

A team of researchers led by Dr. Dao Wen Wang at Huazhong University of Science and Technology has conducted a comprehensive retrospective study analyzing the effects of different diabetes medications on COVID-19 outcomes. This study, involving data from 4,922 patients with COVID-19 and T2DM across 138 hospitals in Hubei Province, China, sheds light on the potential benefits of metformin and alpha-glucosidase inhibitors (AGIs) while raising concerns about insulin use.

The research is published in the journal Molecular Biomedicine.

The study, conducted between December 2019 and August 2021, found a significant association between metformin and AGI use and reduced all-cause mortality in COVID-19 with T2DM. Conversely, insulin use was linked to an increased risk of death. These findings were consistent even after adjusting for age, sex, comorbidities, and other medications.

The researchers utilized various statistical methods, including multivariate Cox regression and propensity score matching, to ensure the robustness of their findings. Subgroup analyses further confirmed the observed associations in different patient populations, including critically ill patients and those with poorly controlled .

This research challenges previous recommendations prioritizing insulin for managing hyperglycemia in COVID-19 patients with T2DM. While the study is retrospective and cannot establish causality, the findings underscore the need for further research and careful consideration when prescribing insulin for this vulnerable population.

Dr. Wang emphasizes, "Our study suggests that metformin and AGIs may be more suitable treatment options for COVID-19 patients with T2DM. Clinicians should exercise caution when considering therapy for these individuals."

More information: Ke Xu et al, Effects of different treatments for type 2 diabetes mellitus on mortality of coronavirus disease from 2019 to 2021 in China: a multi-institutional retrospective study, Molecular Biomedicine (2024). DOI: 10.1186/s43556-024-00183-1

Provided by Sichuan International Medical Exchange and Promotion Association
Citation: Metformin and AGIs show potential for improved outcomes in COVID-19 patients with type 2 diabetes (2024, June 21) retrieved 20 July 2024 from https://medicalxpress.com/news/2024-06-metformin-agis-potential-outcomes-covid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Metformin treatment may decrease the mortality risk in ICU patients with type 2 diabetes and CHF

1 shares

Feedback to editors